CTLA4 and hepatocellular carcinoma: The inflammatory state of the HCC microenvironment makes HCC immunotherapy modalities such as immune checkpoint inhibitors, anti-CTLA4 (cytotoxic T-lymphocyte associated protein 4), and anti-PDCD1/PD-1 (programmed cell death 1) potentially helpful.